The target platelet count for ITP patients should be tailored to their lifestyle, bleeding history, and quality of life goals. A normal platelet count is not necessary, and different thresholds are appropriate for different patients (e.g., someone planning a ski trip versus a sedentary individual).

ITP caused by immune checkpoint inhibitors (ICIs) is rare (0.25% incidence) but generally has a good prognosis. Most patients respond to standard first-line ITP therapies, and approximately 70% of those re-challenged with the ICI can continue treatment without a recurrence of ITP.

Contrary to common assumptions, standard initial steroid therapy is ineffective for the vast majority of adult ITP patients. Approximately 80% progress to chronic disease, highlighting the urgent need for more effective first- and second-line therapies to alter the disease course.

The treatment paradigm for ITP is shifting towards early combination therapy. Recent clinical trials are investigating augmented first- and second-line regimens, such as combining dexamethasone with rituximab or romiplostim, to achieve more durable, treatment-free responses than monotherapy.

Patients with ITP who fail or are intolerant to one TPO receptor agonist (e.g., eltrombopag) should not be considered a class failure. Switching to another TPO agent is a viable strategy that can induce a response in nearly half of these cases, particularly for intolerance.

The LUNA-three trial demonstrated that ITP patients on rilzabrutinib showed improved fatigue. Notably, even patients whose platelet counts did not respond to the drug still had better fatigue outcomes than the placebo group, suggesting a separate anti-inflammatory benefit on quality of life.

The immune system must balance being aggressive against foreign threats while not attacking the body's own cells. T-cells that recognize "self-antigens" sometimes escape the thymus. Autoimmune diseases emerge when these secondary checks fail, causing the immune system to attack healthy tissues like joints or the brain.

Despite updated ASH guidelines suggesting its use, some experts avoid upfront rituximab because it's not disease-modifying and may worsen the long-term autoimmune response. They prefer to reserve it for later-line or salvage settings rather than initial combination therapy.

Named after the two-faced god Janus, yanalumab has a dual mechanism. It acts as a highly potent B-cell depleter while also blocking the BAF receptor pathway, which is critical for auto-reactive B-cell survival. This offers potential for deep, lasting, treatment-free remission.